2. Signaling Pathways
  3. TGF-beta/Smad
  4. TGF-β Receptor
  5. ALK3 Isoform

ALK3

BMPR1A (bone morphogenetic protein receptor type 1A) is also known as ALK3. Though some functions of ALK3 suggest similarity to ALK2, this protein has substantial sequence similarity with a different ALK family member, ALK6. Currently, it is known that many BMPs (BMP2, 4, 5, 6, 7, 8, 14, 15), GDF6, GDF7, and AMH can bind to ALK3 with some affinity to initiate differential downstream action. Global knockout of ALK3 is embryonic lethal. ALK3 is expressed in cells of the osteo lineage and bone marrow and is necessary for post-natal bone formation; as such, it is suggested that the main function of ALK3 is osteogenesis. Mice with conditional knockout of ALK3 in cartilage lack growth of the long bones, however this tissue gets replaced with bone-like tissue, supporting a role of ALK3 in cell fate and osteogenesis. Conditional deletion of Alk3 from osteoblasts produces a similar phenotype. These mice have increased bone formation in the trabecular bone, vertebrae, tail, and ribs, coupled with a reduction in osteoclastogenesis. Unlike ALK2, ALK3 has additional critical roles in development. Deletion of ALK3 in Xenopus results in dorsalized embryos and defects in the eye. Myocardial- and neural crest-specific knockouts of ALK3 show drastic developmental defects. Epicardial-specific deletion of ALK3 in mice results in atypical developmental of the atrioventricular sulcus and annulus fibrosis within the cardia. Additionally, when ALK3 is deleted early (at weaning or early adulthood) from the foregut, mice have improper gastric patterning, as well as a reduced number of parietal cells and increased number of endocrine cells.

Cat. No. Product Name Effect Purity
  • HY-13418A
    Dorsomorphin
    		Inhibitor 99.91%
    Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
  • HY-13418
    Dorsomorphin dihydrochloride
    		Inhibitor 99.91%
    Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
  • HY-12071
    LDN193189
    		Inhibitor 99.48%
    LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.
  • HY-12071A
    LDN193189 Tetrahydrochloride
    		Inhibitor 99.86%
    LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3 (IC50=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC50≥500 nM).
  • HY-15897
    LDN-212854
    		Inhibitor 99.70%
    LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC).
  • HY-12274
    ML347
    		Inhibitor 99.94%
    ML347 (LDN193719) is a highly selective ALK1/ALK2 inhibitor. ML347 has IC50 values of 46 and 32 nM against ALK1 and ALK2, respectively, >300-fold selective over ALK3. ML347 block the phosphorylation of Smad1/5 by TGF-β1.
  • HY-123900
    AZ12799734
    		Inhibitor 98.07%
    AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC50 of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor.
Cat. No. Product Name / Synonyms Species Source